At the news
? NEUTRALIMPACT 2/10 8-K filed Jul 29, 2026 at 17:06 ET
Kura Oncology entered amended executive employment agreements with its CEO, CCO, and COO modifying severance provisions. The changes enhance change-of-control severance benefits (e.g., 24-month salary for CEO in change-of-control termination, full equity acceleration). No departures, appointments, or material financial figures were disclosed.
- CEO Troy E. Wilson's new agreement provides 12 months base salary severance (non-change-of-control) or 24 months + 200% target bonus (change-of-control).
- CCO Brian Powl and COO Kathleen Ford each receive 12 months base salary severance (non-change-of-control) or 18 months + 150% target bonus (change-of-control).
- Change-of-control severance includes full equity acceleration (performance-based awards vest at target) for all three executives.
- Full copies of the agreements will be filed with the Q3 2026 10-Q.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access